Key Findings
The U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for the treatment of adults with thyroid eye disease (TED). This marks the first subcutaneous (SC) treatment option for TED that can be administered at home by the patient or a caregiver. The approval follows a priority review designation and represents the second indication for the drug, which was previously approved for neuromyelitis optica spectrum disorder (NMOSD) in 2020.
Technical Details
Enspryng is a first-in-class anti-IL-6R monoclonal antibody (mAb) utilizing novel recycling antibody technology to inhibit IL-6 signaling upstream of autoantibody-driven pathology. During the maintenance phase, the drug is administered every four weeks.
The approval is supported by the Phase III SatraGO programme, consisting of two identically designed, randomized, placebo-controlled, multicenter studies (SatraGO-1 and SatraGO-2) involving 258 patients across 19 countries. While SatraGO-1 did not meet its pre-specified primary efficacy endpoint at Week 24, SatraGO-2 demonstrated significant results in the active TED population:
- Proptosis response: 52.9% in the Enspryng group vs. 23.4% in the placebo group.
- Diplopia reduction: 60.7% in the Enspryng group vs. 25.8% in the placebo group.
Consistent results were observed in the overall population, including both active and chronic patients. The safety profile remained consistent with the drug’s known profile in NMOSD.
Background & Context
TED, or Graves’ ophthalmopathy, is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the US. It is characterized by inflammation around the eyes, leading to symptoms such as bulging (proptosis), double vision (diplopia), redness, and swelling. If left untreated, the condition can cause facial disfigurement and vision-threatening complications.
Significance & Outlook
The introduction of a subcutaneous option reduces the logistical burden associated with traditional infusion-based therapies. Beyond TED, Enspryng has been accepted by the FDA for priority review in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and is being studied for other neurological autoimmune and inflammatory diseases.
Source: https://www.roche.com/investors/updates/inv-update-2026-10-16
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
